Lyell Immunopharma, Inc. — Director's Dealing 2023

Jun 20, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Lyell Immunopharma, Inc. (LYEL)
CIK: 0001806952
Period of Report: 2023-06-16

Reporting Person: Klausner Richard (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-06-16	Option (right to buy)	$3.19	A	65000	Acquired	2033-06-15	Common Stock (65000)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	2967834	Direct
Common Stock	988900	Indirect

Footnotes

F1: Consists of 250,000 shares held by The Ariella Klausner Delaware Trust, 238,900 shares held by The Eli Klausner Delaware Trust, 250,000 shares held by The Isaac Klausner Delaware Trust, and 250,000 shares held by The Olivia Klausner Delaware Trust. The Reporting Person is a grantor of each of the trusts and disclaims beneficial ownership of all shares held by the trusts except to any pecuniary interest therein. Raymond James Trust Services of Delaware is the trustee of each of the trusts.

F2: The option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following June 16, 2023 (or the date immediately prior to such date if the Reporting Person's service as a director ends at such annual meeting due to the Reporting Person's failure to be reelected
or the Reporting Person not standing for re-election); or (b) the first anniversary of June 16, 2023, subject to the Reporting Person
providing continuous service through such date.